Skip to main content

Table 1 Biometric, serum and metabolic data:

From: Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report

  ZL ZL+S ZDF ZDF+E ZDF+S ZDF+S+E ZDF+S+H P-value
n 9 9 9 8 8 8 7  
Body weight at week 14 (g) 325 ± 5 335 ± 7 341 ± 13 345 ± 9 357 ± 10 347 ± 8 360 ± 9 0.11
Body weight at week 24 (g) 381 ± 7 372 ± 8 362 ± 13 365 ± 13 371 ± 18 348 ± 10 369 ± 13 0.60
Serum glucose levels (mg per 100 ml) at week 14 95 ± 7* 96 ± 9* 377 ± 22 363 ± 15 344 ± 19 375 ± 7 389 ± 24 < 0.001
Serum glucose levels (mg per 100 ml) at week 24 91 ± 7* 83 ± 5* 408 ± 21 425 ± 27 319 ± 30♠ 367 ± 34 364 ± 20 < 0.001
Mean systolic blood pressure over treatment periode (mmHg) 147 ± 3 150 ± 3 134 ± 3¥ 138 ± 3 144 ± 4¥¥ 139 ± 4 140 ± 3 < 0.001
  1. Abbreviations: ZL: Zucker lean on normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + E: Zucker diabetic fatty on eplerenone therapy. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E: Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker diabetic fatty on high salt diet with hydralazine therapy.
  2. Post hoc testing: * P < 0.001 ZL and ZL + S vs. all other groups. ¥ P < 0.001 ZDF vs. ZL. ¥¥ P < 0.01 ZDF + S vs. ZDF. ♠ P < 0.05 ZDF + S vs. ZDF.